Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMAlternative pomalidomide alternative dosing PK/PD pilot study
NL-OMON53932Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pomalidomide, sponsored by Amsterdam University Medical Center. Started Nov 2022; status: completed.
02
Drugs
pomalidomide
Beyond the preview
Go deeper on NL-OMON53932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53932.